In advanced cases, such as anaplastic thyroid cancer (ATC), recent therapeutic developments have focused on mutation-specific inhibitors - such as dabrafenib and trametinib for B-Raf proto-oncogene (BRAF)-mutated ATC - as well as immune checkpoint inhibitors, aiming to enhance clinical outcomes[5]. The gene discussed is BRAF; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.